• am3025

CHF Currency Report | Nov 19 2020

Updated: Nov 28, 2020

Since the beginning of the week (11/16), the Swissie (CHF) has been trending downward against the US dollar, depreciating 0.105% to $1.0949/USD. Given that CHF is typically considered a safe haven currency and performs well when there is a risk-off sentiment. Therefore, such a depreciation can be attributed to a multitude of factors such as Pfizer and Moderna announcing effective coronavirus vaccines with efficacy rates of 94% and 95%.

However, positive economic data has softened the impact of this vaccine news:

· Balance of Trade for the month of October (CHF 2.9B) increased from September (CHF2.4B),

· Industrial Production YOY Q3 at -5.1% improved from -9.3% in Q2

· Unemployment rate stayed the same for October 3.2%

Since August, the CHF/USD pair has been trapped on a monthly basis between a resistance and support range of 1.11 and 1.077 respectively, as seen in the spot chat below.

Assuming the USD/CHF fails to breach the resistance level of 1.11, traders may see a bearish direction in the week to come back towards the lower support level of 1.077. This is positive news for Switzerland’s large export business.

Comments from SNB

After appreciating considerably during 2020, the Swissie continues to face contractionary measures implemented by the central bank. The Swiss National Bank (SNB) has spent US$97 billion since March 2020 to control the currency’s appreciation. Fritz Zurbruegg, SNB vice-chairman, announced on 18th November that the institution will continue this spending by increasing its foreign currency holdings to prevent any additional rise.

Upcoming events likely to influence the CHF are:

· Switzerland’s Economic Sentiment Index (due 25 NOV);

· Retail sales YoY for October (due 30 NOV); and

· KOF Leading Indicators (due 30 NOV).

12 views0 comments
Deaglo white logo.png
  • LinkedIn - White Circle

All statements of opinion and/or belief contained in this website and all views expressed represent Deaglo Partners LLC's “Deaglo” own assessment and interpretation of information available to it at the date of this website. The information contained in this website is based on publicly available information only, from third-party sources. Deaglo does not represent that it is accurate, timely, comprehensive or complete and it should not be relied upon as such, nor has it been independently verified. No reliance may be placed for any purposes whatsoever on the information contained in this website. Under no circumstances should the information provided in this website be considered as investment or trading advice, or as a sufficient basis on which to make any investment or trading decisions and is provided to you for information purposes only. Whilst this website has been prepared in good faith, Deaglo and its group undertakings, members and employees from time to time (“Affiliates”) do not make and are not authorized to make any representation, warranty, or undertaking, express or implied, with respect to the information or opinions contained in it and no responsibility or liability is accepted by any of them as to the accuracy, completeness or reasonableness of such information or opinions or any other written or oral information made available to you. Without prejudice to the foregoing and to the fullest extent permitted by law, Deaglo and its Affiliates do not accept any liability whatsoever for any loss however arising, directly or indirectly, from use of this website or otherwise arising in connection therewith. Nothing herein shall not exclude any liability for, or remedy in respect of, fraud or fraudulent misrepresentation. Our professionals may provide oral or written market commentary or trading strategies to our clients. Deaglo will not treat recipients as clients by virtue of their receiving this report. Data may be subject to updates and corrections without notice. No part of this material may be (i) copied or duplicated in any form by any means or (ii) redistributed without the prior written consent of Deaglo.